Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Net Income towards Common Stockholders (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Net Income towards Common Stockholders for 15 consecutive years, with $23.9 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 21.34% to $23.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.2 million through Dec 2025, down 29.74% year-over-year, with the annual reading at $98.2 million for FY2025, 29.74% down from the prior year.
  • Net Income towards Common Stockholders hit $23.9 million in Q4 2025 for Corcept Therapeutics, up from $19.4 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $46.7 million in Q3 2024 to a low of $15.8 million in Q1 2023.
  • Historically, Net Income towards Common Stockholders has averaged $27.9 million across 5 years, with a median of $27.5 million in 2022.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 88.37% in 2023 and later crashed 58.54% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at $32.1 million in 2021, then plummeted by 48.42% to $16.5 million in 2022, then skyrocketed by 88.37% to $31.1 million in 2023, then dropped by 2.42% to $30.4 million in 2024, then dropped by 21.34% to $23.9 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for CORT at $23.9 million in Q4 2025, $19.4 million in Q3 2025, and $34.6 million in Q2 2025.